Soluble mannose receptor CD206 and von Willebrand factor are early biomarkers to identify patients at risk for severe or necrotizing acute pancreatitis.
Acute pancreatitis
Endothelial activation
Macrophage activation
Necrotizing pancreatitis
Journal
Journal of intensive care
ISSN: 2052-0492
Titre abrégé: J Intensive Care
Pays: England
ID NLM: 101627304
Informations de publication
Date de publication:
11 Jun 2022
11 Jun 2022
Historique:
received:
05
01
2022
accepted:
30
05
2022
entrez:
11
6
2022
pubmed:
12
6
2022
medline:
12
6
2022
Statut:
epublish
Résumé
In acute pancreatitis (AP), microcirculatory dysfunction and leukocyte activation contribute to organ damage, inflammation, and mortality. Given the role of macrophage activation, monocyte recruitment, and microthrombus formation in the early pathogenesis of AP, we examined the macrophage activation marker soluble mannose receptor (sCD206) and the endothelial function marker von Willebrand factor (vWF) in patients admitted for AP. In an exploratory analysis, serum sCD206 and plasma vWF were prospectively analyzed on day 1 and day 3 in 81 patients with AP admitted to the hospital. In addition, blood samples from 59 patients with early AP admitted to the intensive care unit and symptom onset < 24 h were retrospectively analyzed. Patients were dichotomized as per study protocol into two groups: (i) "non-severe edematous AP" including patients with mild AP without organ failure and patients with transient organ failure that resolves within 48 h and (ii) "severe/necrotizing AP" including patients with severe AP and persistent organ failure > 48 h and/or patients with local complications. In the prospective cohort, 17% developed severe/necrotizing pancreatitis compared with 56% in the ICU cohort. Serum concentrations of sCD206 on admission were higher in patients with severe/necrotizing AP than in patients with non-severe edematous AP (prospective: 1.57 vs. 0.66 mg/l, P = 0.005; ICU: 1.76 vs. 1.25 mg/l, P = 0.006), whereas other inflammatory markers (leukocytes, C-reactive protein, procalcitonin) and disease severity (SOFA, SAPS II, APACHE II) did not show significant differences. Patients with severe/necrotizing AP had a greater increase in sCD206 than patients with non-severe edematous AP at day 3 in the prospective cohort. In contrast to routine coagulation parameters, vWF antigen levels were elevated on admission (prospective cohort: 375 vs. 257%, P = 0.02; ICU cohort: 240 vs. 184%, P = 0.03). When used as continuous variables, sCD206 and VWF antigen remained predictors of severe/necrotizing AP after adjustment for etiology and age in both cohorts. sCD206 identifies patients at risk of severe AP at earlier timepoints than routine markers of inflammation and coagulation. Prospective studies are needed to investigate whether incorporating early or repeated measurements into the existing scoring system will better identify patients at increased risk for complications of AP.
Sections du résumé
BACKGROUND
BACKGROUND
In acute pancreatitis (AP), microcirculatory dysfunction and leukocyte activation contribute to organ damage, inflammation, and mortality. Given the role of macrophage activation, monocyte recruitment, and microthrombus formation in the early pathogenesis of AP, we examined the macrophage activation marker soluble mannose receptor (sCD206) and the endothelial function marker von Willebrand factor (vWF) in patients admitted for AP.
METHODS
METHODS
In an exploratory analysis, serum sCD206 and plasma vWF were prospectively analyzed on day 1 and day 3 in 81 patients with AP admitted to the hospital. In addition, blood samples from 59 patients with early AP admitted to the intensive care unit and symptom onset < 24 h were retrospectively analyzed. Patients were dichotomized as per study protocol into two groups: (i) "non-severe edematous AP" including patients with mild AP without organ failure and patients with transient organ failure that resolves within 48 h and (ii) "severe/necrotizing AP" including patients with severe AP and persistent organ failure > 48 h and/or patients with local complications.
RESULTS
RESULTS
In the prospective cohort, 17% developed severe/necrotizing pancreatitis compared with 56% in the ICU cohort. Serum concentrations of sCD206 on admission were higher in patients with severe/necrotizing AP than in patients with non-severe edematous AP (prospective: 1.57 vs. 0.66 mg/l, P = 0.005; ICU: 1.76 vs. 1.25 mg/l, P = 0.006), whereas other inflammatory markers (leukocytes, C-reactive protein, procalcitonin) and disease severity (SOFA, SAPS II, APACHE II) did not show significant differences. Patients with severe/necrotizing AP had a greater increase in sCD206 than patients with non-severe edematous AP at day 3 in the prospective cohort. In contrast to routine coagulation parameters, vWF antigen levels were elevated on admission (prospective cohort: 375 vs. 257%, P = 0.02; ICU cohort: 240 vs. 184%, P = 0.03). When used as continuous variables, sCD206 and VWF antigen remained predictors of severe/necrotizing AP after adjustment for etiology and age in both cohorts.
CONCLUSIONS
CONCLUSIONS
sCD206 identifies patients at risk of severe AP at earlier timepoints than routine markers of inflammation and coagulation. Prospective studies are needed to investigate whether incorporating early or repeated measurements into the existing scoring system will better identify patients at increased risk for complications of AP.
Identifiants
pubmed: 35690841
doi: 10.1186/s40560-022-00619-2
pii: 10.1186/s40560-022-00619-2
pmc: PMC9188125
doi:
Types de publication
Journal Article
Langues
eng
Pagination
28Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 403224013/B07
Informations de copyright
© 2022. The Author(s).
Références
Lancet. 1989 Jul 22;2(8656):201-5
pubmed: 2568529
Pancreatology. 2016 Jan-Feb;16(1):52-6
pubmed: 26610611
Thromb Haemost. 2005 Mar;93(3):554-8
pubmed: 15735809
Scand J Gastroenterol. 2008;43(11):1387-96
pubmed: 18609162
Immunol Lett. 2019 Feb;206:28-32
pubmed: 30521839
Crit Care Med. 2002 Jun;30(6):1274-9
pubmed: 12072681
Leuk Res. 2015 Sep;39(9):971-5
pubmed: 26169445
Scand J Clin Lab Invest. 2018 May;78(3):180-186
pubmed: 29383956
Thromb Haemost. 2011 Jan;105(1):145-53
pubmed: 21057705
Gastroenterology. 2018 Feb;154(3):704-718.e10
pubmed: 29079517
Surg Gynecol Obstet. 1974 Jul;139(1):69-81
pubmed: 4834279
Ann Surg. 2009 Nov;250(5):712-9
pubmed: 19801929
Pancreatology. 2001;1(4):356-62
pubmed: 12120214
Crit Care. 2003 Feb;7(1):23-38
pubmed: 12617738
Gut. 2013 Jan;62(1):102-11
pubmed: 23100216
Blood. 1996 May 15;87(10):4235-44
pubmed: 8639782
J Leukoc Biol. 2019 Nov;106(5):1129-1138
pubmed: 31242338
J Hepatol. 2016 Apr;64(4):813-22
pubmed: 26639396
J Thromb Haemost. 2007 Nov;5(11):2284-90
pubmed: 17764538
Nat Rev Microbiol. 2016 Mar;14(3):163-76
pubmed: 26853116
Shock. 1998 Sep;10(3):169-75
pubmed: 9744644
Pancreas. 2000 May;20(4):367-72
pubmed: 10824690
Gastroenterology. 2018 Aug;155(2):469-478.e1
pubmed: 29660323
Gastroenterol Res Pract. 2019 Mar 10;2019:8201096
pubmed: 30984258
Haematologica. 2003 Sep;88(9):1029-34
pubmed: 12969811
Int J Mol Sci. 2019 Jul 30;20(15):
pubmed: 31366007
Gut. 2017 Nov;66(11):2024-2032
pubmed: 28838972
J Biol Chem. 2011 Mar 11;286(10):7822-7829
pubmed: 21205820
Gastroenterology. 2020 May;158(6):1745-1761
pubmed: 31982413
Gastroenterology. 2012 Jun;142(7):1476-82; quiz e15-6
pubmed: 22425589
Eur J Gastroenterol Hepatol. 2015 Jun;27(6):728-34
pubmed: 25923947
Scand J Gastroenterol. 2011 Mar;46(3):261-70
pubmed: 21067283
Nat Rev Immunol. 2003 Jan;3(1):23-35
pubmed: 12511873
Liver Int. 2015 Jan;35(1):37-45
pubmed: 25113276
Pancreatology. 2017 Nov - Dec;17(6):893-897
pubmed: 29030078
Ann Surg. 2012 Dec;256(6):875-80
pubmed: 22735715
Front Physiol. 2018 Aug 30;9:1215
pubmed: 30214418
Circulation. 2004 Jun 8;109(22):2698-704
pubmed: 15184294
Gastroenterology. 2019 May;156(7):1994-2007.e3
pubmed: 30776347
Microbes Infect. 2000 Sep;2(11):1305-10
pubmed: 11018446
Br J Haematol. 1981 Sep;49(1):61-8
pubmed: 6791681
Indian J Med Microbiol. 2017 Jul-Sep;35(3):376-380
pubmed: 29063882
Pancreas. 2017 Apr;46(4):482-488
pubmed: 28196021
J Biochem. 2001 Oct;130(4):475-80
pubmed: 11574066
Pancreatology. 2001;1(3):224-9
pubmed: 12120199
Inflamm Res. 2019 Aug;68(8):677-689
pubmed: 31139836
Br J Haematol. 2005 Nov;131(4):417-30
pubmed: 16281932
J Clin Invest. 1986 Dec;78(6):1456-61
pubmed: 3491092
Blood. 2006 Jan 15;107(2):528-34
pubmed: 16189276
Histochem Cell Biol. 2016 Jun;145(6):659-73
pubmed: 26860866
Hepatogastroenterology. 2001 Nov-Dec;48(42):1746-9
pubmed: 11813615
Blood. 1999 Jul 1;94(1):179-85
pubmed: 10381511
United European Gastroenterol J. 2019 May;7(4):557-564
pubmed: 31065373
Gastroenterology. 2021 Dec;161(6):2014-2029.e14
pubmed: 34450180
World J Emerg Surg. 2019 Jun 13;14:27
pubmed: 31210778
Eur J Clin Microbiol Infect Dis. 2014 Jan;33(1):117-22
pubmed: 24424890
Br J Surg. 2006 May;93(5):518-30
pubmed: 16607683
Aliment Pharmacol Ther. 2018 Mar;47(5):657-664
pubmed: 29266346
Pancreatology. 2017 Jan - Feb;17(1):45-50
pubmed: 28007459
Crit Care. 2019 Aug 2;23(1):270
pubmed: 31375142
Blood. 1993 Feb 1;81(3):720-5
pubmed: 8427964
Gut. 2004 Sep;53(9):1340-4
pubmed: 15306596
PLoS One. 2015 Jun 19;10(6):e0130412
pubmed: 26091293
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560